anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

207,301-207,360 of 319,975

filter-aware
19
The chart shows dose-response curves for cell binding. The table summarizes EC50 values.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
20
The chart shows a biphasic exponential decay curve for three datasets.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
21
The chart uses a regression line to correlate human and NHP half-lives, highlighting the 3.1x multiplier for YTE-modified antibodies.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
22
The slide uses a visual timeline/comparison to contrast the high injection frequency of the competitor with the lower frequency of SPY001.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
23
The chart combines a bar chart of competitor benchmarks with a bar chart showing vedolizumab's exposure-response quartiles.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
24
Data from GEMINI 1 study; compares Q8W and Q4W dosing regimens.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
25
Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slidesAeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
26
The slide uses a dual-axis approach: a bar chart for valuation benchmarks and a timeline for clinical milestones.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
27
The slide uses a visual pipeline format to track progress from Discovery to Clinical stages for specific drug candidates.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
28
The chart compares clinical remission rates across different drug classes (TL1A, a4b7, IL-23s, TNFas, S1P1s, JAKs) with a safety gradient indicated on the Y-axis.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
29
Uses a checkmark matrix to highlight competitive advantages of SPY002.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
30
The slide uses an antibody diagram to annotate specific technical advantages of the SPY002 molecule.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
31
The slide uses a bar chart to compare efficacy and provides a strategic rationale for pursuing both monomeric/trimeric and trimeric-only approaches.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
32
Includes two charts: a dose-response curve and a scatter plot of potency vs. binding specificity.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
33
The table contrasts established drugs (with confirmed exposure-response) against newer anti-TL1A agents (PRA023, RVT-3101) where this relationship is currently TBD.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
34
The slide uses a 2x2 grid to summarize program strengths and a timeline for catalysts.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
35
The slide uses a mountain-climbing metaphor to represent indication expansion.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
36
The slide uses a Gantt-style visualization to show the progress of various drug candidates (SPY001-SPY230).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
37
The slide uses a biological process diagram to illustrate drug targets (a4b7, TL1A, IL-23) and their corresponding therapeutic antibodies.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
38
The slide uses a bar chart to illustrate additive clinical remission rates, with a table below providing additional clinical metrics (N, maintenance remission, safety).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
39
The slide uses donut charts to represent remission rates and highlights the safety advantages of Spyre's gut-selective approach.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
40
Includes a specific note that this is an 'Illustrative example' and 'Preliminary; pending regulatory feedback'.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
41
The slide uses a bispecific antibody illustration to represent the combination therapy approach.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
42
The slide uses a Venn diagram to illustrate target overlap and a hierarchical tree to show potential combination therapy paths.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
43
The slide uses a comparative bar chart structure to show the delta in efficacy when using a companion diagnostic (CDx).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
44
Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slidesAeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
45
The slide displays headshots of leadership and board members, followed by a grid of company logos representing their backgrounds or affiliations.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
46
The slide uses a table-based timeline format to track R&D progress and external data readouts.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
47
The table uses a custom visualization for market cap range (min, IPO, today, max) and clinical stage progression.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
48
The table maps historical industry M&A deals to Spyre's internal pipeline development milestones (2025-2027).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
49
Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slidesAeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
50
The slide uses a list-based format to highlight key organizational milestones and metrics.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
01
Slide 1
Alkermes | Investor Presentation Deck | 56 slidesAlkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations 1 hit
02
Includes company overview, forward-looking statement safe harbor, SEC filing information, non-GAAP definition, and trademark disclosures.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations 1 hit
03
Alkermes | Investor Presentation Deck | 56 slidesAlkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations 1 hit
04
Alkermes | Investor Presentation Deck | 56 slidesAlkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Current Reality (Pain)1 hit
05
This is a classic 'preempt_rebuttal' style slide used in proxy contests to defend the incumbent board.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Current Reality (Pain)1 hit
06
Alkermes | Investor Presentation Deck | 56 slidesAlkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Current Reality (Pain)1 hit
07
The slide uses a four-column layout to summarize key business pillars.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Current Reality (Pain)1 hit
08
The slide uses a three-column layout to present strategic priorities, with a footer highlighting stock performance relative to peers.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Future Vision (Gain)1 hit
09
Alkermes | Investor Presentation Deck | 56 slidesAlkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Future Vision (Gain)1 hit
10
The slide uses a numbered list format to map strategic pillars to specific results.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Future Vision (Gain)Loop · Before After1 hit
11
The slide uses three bar charts to demonstrate superior performance of ALKS relative to benchmarks.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Future Vision (Gain)Loop · Before After1 hit
12
The slide uses bar charts to demonstrate performance relative to an 'unaffected date' related to a shareholder activist event.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Future Vision (Gain)Loop · Before After1 hit
13
The slide highlights a 50% improvement in valuation multiple despite a decline in the NBI index multiple.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Evidence & ProofLoop · Before After1 hit
14
Alkermes | Investor Presentation Deck | 56 slidesAlkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Evidence & Proof1 hit
15
The slide highlights board changes, including specific appointments with shareholder support and the addition of diverse skill sets.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Evidence & Proof1 hit
16
The slide uses a dual-axis timeline (top and bottom) to annotate events on a stock price chart.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Evidence & Proof1 hit
17
The table categorizes products into 'Proprietary' and 'Royalty' streams.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Evidence & ProofLoop · Mece Breakdown1 hit
18
The slide uses a mix of bar charts for annual revenue and a line chart for weekly prescription growth.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Evidence & ProofLoop · Mece Breakdown1 hit
19
The slide uses a bar chart to show quarterly net sales growth from Q4'21 to Q1'23.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Evidence & ProofLoop · Mece Breakdown1 hit
20
The slide uses donut charts to represent revenue composition and growth.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Evidence & ProofLoop · Mece Breakdown1 hit
21
Uses a before-after comparison of drug development stages (Gantt-style pipeline).Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations 1 hit
22
Alkermes | Investor Presentation Deck | 56 slidesAlkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations 1 hit
23
The chart uses a break in the x-axis to transition from historical data (2020-2022) to future projections (2024-2025).Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations 1 hit
24
The slide uses a chronological sequence to demonstrate management's effective handling of a major revenue threat.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations 1 hit
25
The slide uses a hub-and-spoke diagram to show the core Alkermes business and a separate branch for the oncology spin-off.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations 1 hit
26
The slide uses a two-column layout to contrast the board's strategic rationale with the specific value propositions of the resulting companies.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations 1 hit
27
Alkermes | Investor Presentation Deck | 56 slidesAlkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations 1 hit
28
The slide uses a grid layout with headshots, biographical bullet points, and committee membership indicators.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations 1 hit